Export

Glecaprevir + pibrentasvir
Essential medicine status
General description

INN
Glecaprevir + pibrentasvir
Medicine type
Chemical agent
EML status history
First added in 2019 (TRS 1021) for Chronic hepatitis C
Changed in 2019 (TRS 1021) for Chronic hepatitis C
Changed in 2019 (TRS 1021) for Chronic hepatitis C
Changed in 2019 (TRS 1021) for Chronic hepatitis C
Therapeutic equivalent for
daclatasvir for Chronic hepatitis C
sofosbuvir for Chronic hepatitis C
sofosbuvir + velpatasvir for Chronic hepatitis C
Wikipedia
Glecaprevir + pibrentasvir
DrugBank
Glecaprevir ,
Pibrentasvir
Recommendations
Section
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
  • Oral > Solid: 100 mg + 40 mg tablet
Indications
Chronic hepatitis C